Michael S. Fazekas michael.fazekas.wg11@wharton.upenn.edu


University of Chicago, Chicago, IL B.A., With Honors, Economics, 2005


Sarah E. Frew, Ph.D.


sarah.frew.wg11@wharton.upenn.edu Carnegie Mellon University, Pittsburgh, PA B.S., University Honors, Biological Sciences, 1998


Massachusetts Institute of Technology, Cambridge, MA Ph.D., Biology, 2004


Allison F. Gaw


allison.gaw.wg11@wharton.upenn.edu Stanford University, Palo Alto, CA B.S., Honors, Biological Sciences, 2005 M.S., Biological Sciences, 2006


An opportunity to build successful businesses through health care focused private equity investing.


BarrierSafe Solutions, Lake Forest, IL Intern, Linden Portfolio Company, Summer 2010


Managed due diligence, lender com- munication and integration planning for the asset purchase of a disposable glove business. Performed a statistical analysis of the impact of commodity prices on segment level profitability. Presented results to the Board, which decided to implement findings to improve budgeting, inventory purchasing, and supplier negotiation processes.


Flexpoint Ford, Chicago, IL Associate, 2007-2009


Evaluated health care and financial services investments for the firm’s $225M inaugural fund and $1.3B second fund. Led top-down industry analyses, developed new relationships with executives and identified invest- ment opportunities. Worked with portfolio companies to execute their strategic plans, improve operations, manage capital needs, and identify acquisition targets.


J.P. Morgan Securities, Chicago, IL Investment Banking Analyst, 2005-2007 Worked across industries and invest- ment banking products (debt, equity, and M&A) and focused on middle market companies with values that ranged from $200M to $2B. Developed transaction experience, performed valuation analyses, and presented analyses to clients’ executive teams.


An opportunity within an entrepreneur- ial team to build and develop innova- tive biopharmaceutical ventures.


Commons Capital, Brookline, MA Part-Time Associate, 2010–Present Identified potential biotechnology deal flow in emerging markets and conducted preliminary due diligence on new investment opportunities.


Genzyme Corporation, Cambridge, MA Summer Associate, New Business Initiatives, Summer 2010


Performed due diligence on potential M&A and licensing deals in Brazil and participated in face-to-face meetings with C-level managers of investment targets. Presented recommendations to senior management regarding implementation strategies for renal, cardiovascular, and personalized genetic health businesses.


McLaughlin-Rotman Centre for Global Health, Toronto, ON Senior Research Associate & Team Leader, 2004-2009


Initiated and managed a $2.5M, 6-person research program to analyze the strategies of homegrown biophar- maceutical firms in emerging markets to commercialize products for local diseases. Conducted interviews with senior management from more than 60 innovative therapeutics, vaccines, and diagnostics firms in India, China, Brazil, and South Africa, and published findings in renowned academic journals. Developed emerging markets domain expertise across the biopharmaceutical value chain, including regulatory policies, intellectual property portfolios and commercial strategies.


An opportunity in strategy or business development for a biopharmaceuticals company.


Genentech, South San Francisco, CA ACTEMRA Market Planning Intern, Summer 2010


Investigated access and reimburse- ment barriers affecting launch year adoption with qualitative market research and coordination of cross- functional team. Recommendations to brand marketing team and senior leadership received enthusiastically as critical to driving direction of marketing tactics, saving efforts pursing non-essential directions. Actively managed third-party vendor conducting primary research with daily communication to ensure smooth process and quality reports that exceeded previous efforts from vendor.


L.E.K. Consulting, San Francisco, CA Associate Consultant, 2008-2009 Associate, 2006-2008


Completed 20+ cases on pharmaceuti- cal drug development and diagnostics market strategy including M&A valua- tion, clinical development, pricing, and sales and marketing support. Built comprehensive models covering market penetration, revenue fore- casts, and valuation, and physician office P&Ls. Example cases include 1) developing launch pricing strategy for late-to-market next-generation DNA sequencing instrument of current market leader resulting in successful market share gains and 2) evaluating revenue forecasts, industry trends and customer perceptions of an international CMO to prepare successful due diligence bid for Indian conglomerate client.


14


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40